Press Releases
Company News
View Summary FDA Accepts for Review Supplemental New Drug Application for XTANDI(R) (enzalutamide) Capsules in Metastatic Castration-Resistant Prostate Cancer With Data From Head-to-Head Studies of Enzalutamide Versus Bicalutamide
Feb 22, 2016
PDF 337.6 KB Add to Briefcase
View Summary Medivation Announces Fourth Quarter and Year-End 2015 Financial Results Teleconference on February 25, 2016
Feb 11, 2016
PDF 9.4 KB Add to Briefcase
View Summary Medivation to Present at Leerink Partners 5th Annual Global Healthcare Conference
Jan 27, 2016
PDF 9.4 KB Add to Briefcase
View Summary Journal of Clinical Oncology Publishes Results From the STRIVE Trial of Enzalutamide Compared to Bicalutamide in Castration-Resistant Prostate Cancer
Jan 26, 2016
PDF 95.4 KB Add to Briefcase
View Summary Lancet Oncology Publishes Results From the Phase 2 TERRAIN Trial of Enzalutamide Compared to Bicalutamide in Metastatic Castration-Resistant Prostate Cancer
Jan 13, 2016
PDF 95.4 KB Add to Briefcase
View Summary Medivation Names Marion McCourt Chief Operating Officer
Jan 11, 2016
PDF 10.9 KB Add to Briefcase
View Summary NanoString Technologies Enters Into Collaboration Agreement With Medivation and Astellas to Develop Novel Companion Diagnostic Test
Jan 7, 2016
PDF 72.8 KB Add to Briefcase
View Summary Medivation to Present at J.P. Morgan Healthcare Conference
Jan 4, 2016
PDF 9.1 KB Add to Briefcase
View Summary Medivation Initiates Pivotal Clinical Trial of MDV9300 in Diffuse Large B-Cell Lymphoma
Dec 21, 2015
PDF 11.8 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Nov 6, 2015
PDF 9.1 KB Add to Briefcase
View Summary Medivation Reports Third Quarter 2015 Financial Results
Nov 5, 2015
PDF 187.6 KB Add to Briefcase
View Summary Medivation Announces Third Quarter 2015 Financial Results Teleconference on November 5, 2015
Oct 22, 2015
PDF 9.1 KB Add to Briefcase
View Summary Medivation Announces Management Changes
Sep 29, 2015
PDF 12.5 KB Add to Briefcase
View Summary Updated Enzalutamide Data in Triple-Negative Breast Cancer Presented at the 2015 European Cancer Congress
Sep 26, 2015
PDF 62.7 KB Add to Briefcase
View Summary Medivation Effects a Stock Dividend on Its Common Stock
Sep 16, 2015
PDF 8.6 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Sep 3, 2015
PDF 9.2 KB Add to Briefcase
View Summary Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin
Aug 24, 2015
PDF 15.3 KB Add to Briefcase
View Summary Medivation Reports Second Quarter 2015 Financial Results
Aug 6, 2015
PDF 189.3 KB Add to Briefcase
View Summary Medivation Announces Second Quarter 2015 Financial Results Teleconference on August 6, 2015
Jul 16, 2015
PDF 9.0 KB Add to Briefcase
View Summary Medivation Voted Three Years in a Row Among Top Workplaces in the San Francisco Bay Area
Jun 29, 2015
PDF 9.7 KB Add to Briefcase
Showing 21-40 of 373 Page: 1 2 3 4 5 6 ... 19  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Top